Abstract 766P
Background
Prolongation of overall treatment time (OTT) in carcinoma cervix is well known to adversely affect local control and survival. The OTT would be unduly prolonged if brachytherapy (BT) was started only after completion of external beam radiation (EBRT) as multiple insertions are required for high-dose-rate BT. This study was carried out to compare treatment outcomes of shortening the OTT by interdigitated BT as opposed to conventional sequential BT in terms of late toxicities, disease free survival (DFS) and overall survival (OS).
Methods
The study included 70 patients of cancer cervix who met the inclusion criteria. Patients were randomized into study and control arms. All the patients received EBRT (45Gy/20 fractions over 4 weeks) with concurrent Cisplatin and 3 fractions of BT (7 Gy/fraction). Patients in the control arm received weekly BT after one week following EBRT to complete the entire treatment in 7 weeks. In the study arm, BT was interdigitated with EBRT after 15 fractions. Subsequent BT fractions were given on days 27 and 34 to complete the treatment in 5 weeks. The two groups were compared in terms of late toxicities, DFS and OS at a follow up of two years.
Results
A total of 63 patients completed the planned treatment. The OTT and mean biologically equivalent dose (BED10Gy) after reduction for accelerated repopulation was significantly better in the study arm (p=0.001). At two years of follow up, 80% of patients in the study arm and 72.72% in the control arm had no local or distant failure. Also, death occurred in 13.33% patients and 18.18% patients in the study and control arm, respectively. No statistically significant difference was reached in terms of OS and DFS despite a trend towards better DFS in the interdigitated BT arm. The incidence of late lower gastro-intestinal toxicities was found to be higher in the study arm but this difference was not significant.
Conclusions
Interdigitated BT with chemoradiation appears to be an acceptable option for shortening OTT with similar survival outcomes and acceptable toxicities in comparison to sequential brachytherapy. Owing to a shorter OTT, this approach is radiobiologically superior with a more efficient utilization of machines at centers with heavy patient load.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11